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The activity of omiganan pentahydrochloride (formerly MBI 226; a synthetic cationic peptide) was assessed
against 1,437 recent clinical bacterial isolates and 214 recent clinical yeast isolates. The omiganan was highly
active, and minimal bactericidal concentrations or minimal fungicidal concentrations were either equal to or
two- to fourfold higher than MICs. Kill curve experiments showed a clear pattern of bactericidal activity.
Omiganan pentahydrochloride (formerly MBI 226) is a nov-
el topical cationic peptide (sequence: ILRWPWWPWRRK-
amide) analog of indolicidin that was originally purified from
the cytoplasmic granules of bovine neutrophils (5). Omiganan
pentahydrochloride has demonstrated in vitro activity against a
wide variety of microorganisms, including gram-positive and
-negative bacteria and fungi (D. J. Hoban, E. Witwicki, G. C.
Zhanel, L. Palatnick, and H. D. Friedland, Abstr. 42nd Inter-
sci. Conf. Antimicrob. Agents Chemother., abstr. E-1647, 2002),
and can be used in venous catheter care (6, 7). This compound
is rapidly microbicidal and interacts with the cytoplasmic mem-
branes of both gram-positive and -negative bacteria (3; D.
Dugouard, C. Pasetka, D. Erfle, E. Rubinchik, K. Lee, H. D.
Friedland, and P. McNicol, Abstr. 102nd Gen. Meet. Am. Soc.
Microbiol., abstr. A-46, p. 9-10, 2002). In Staphylococcus au-
reus, omiganan pentahydrochloride acts by depolarizing the
cytoplasmic membrane, resulting in cell disruption and death.
This compound also shows a dose-dependent inhibitory effect
on whole-cell protein, RNA, and DNA synthesis in S. aureus
(D. Dugouard, C. Pasetka, D. Erfle, E. Rubinchik, M. Guarna,
P. McNicol, and H. D. Friedland, Abstr. 102nd Gen. Meet.
Am. Soc. Microbiol., abstr. A-47, p. 10, 2002). The exposure of
Escherichia coli to omiganan pentahydrochloride resulted in
outer membrane permeabilization (D. Dugouard et al., Abstr.
102nd Gen. Meet. Am. Soc. Microbiol., abstr. A-46). A topical
1% gel preparation of omiganan is currently in phase III clin-
ical trials for the prevention of catheter-related bloodstream
infections (5, 6, 7).
The purpose of this study was to evaluate the in vitro anti-
microbial activity of omiganan pentahydrochloride against re-
cent clinical isolates of bacteria and Candida. We also evalu-
ated the bactericidal activity of omiganan pentahydrochloride
and its stability in frozen storage after the preparation of ref-
erence broth microdilution panels.
A total of 1,651 clinical strains were tested against omiganan
pentahydrochloride and other selected comparator antimicro-
bial agents. Bacterial strains (n  1,437) were tested in both
cation-adjusted (CA) and -unadjusted (UA) Mueller-Hinton
(MH) broth. Two hundred fourteen Candida sp. strains were
tested in RPMI 1640 broth with MOPS (morpholinepropane-
sulfonic acid) buffer. Approximately one-half of these isolates
were obtained from the omiganan pentahydrochloride clinical
trials.
For the bacterial isolates, susceptibility testing was per-
formed by using NCCLS reference broth microdilution meth-
ods (11). Omiganan pentahydrochloride reagent grade com-
pound was provided by Micrologix Biotech, Inc. (Vancouver,
Canada). Comparator agents were purchased from Sigma
Chemical Co. (St. Louis, Mo.) or obtained from their respec-
tive manufacturers in the United States. Up to 13 comparators
were evaluated, depending upon the species tested. Commer-
cially prepared frozen broth microdilution panels (Sensititre/
TREK Diagnostics, Cleveland, Ohio) were thawed and inocu-
lated with a final inoculum concentration of approximately 5
105 CFU/ml. The bacterial isolates were tested in CA and UA
MH broth. Panels were read manually, and an endpoint of no
visible growth was established as the MIC, per NCCLS criteria
(12). Concurrent quality control (QC) studies were performed
by testing control strains, which were Streptococcus pneumo-
niae ATCC 49619, Enterococcus faecalis ATCC 29212, S. au-
reus ATCC 29213, E. coli ATCC 25922, and Pseudomonas
aeruginosa ATCC 27853. A study was previously performed to
establish QC ranges for omiganan pentahydrochloride for five
bacterial American Type Culture Collection (ATCC) strains
and two yeast ATCC strains (T. R. Anderegg, T. R. Fritsche,
R. N. Jones, and the Quality Control Working Group, Letter,
J. Clin. Microbiol. 42:1386-1387, 2004). Colony counts were
performed weekly to ensure the inoculum of approximately
3  105 to 7  105 CFU per ml.
For the yeast isolates, a suspension equal to a 0.5 McFarland
standard was made, diluted 1:500 in RPMI 1640 broth with
MOPS buffer, and inoculated into the thawed panels to a final
concentration of 0.5  103 to 2.5  103 CFU/ml. Panels were
incubated in an ambient air environment at 35°C and were
read at 24 and 48 h of growth (1, 2, 10). QC was performed by
testing the following ATCC strains: Candida parapsilosis
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TABLE 1. Antimicrobial activities of omiganan pentahydrochloride and selected comparator antimicrobial agents
against 1,651 strains of bacteria and Candida spp.
Organism (no. tested) and
antimicrobial agenta
MIC (g/ml) % by categoryb
50% 90% Range Susceptible Resistant
Oxacillin-susceptible CoNS (44)
Omiganan pentahydrochloride (CA MH broth) 4 8 0.5–8 — —
Omiganan pentahydrochloride (UA MH broth) 2 4 0.5–4 — —
Vancomycin 1 2 0.25–2 100.0 0.0
Penicillin 0.25 4 0.06–8 36.4 63.6
Ciprofloxacin 0.25 0.5 0.25–2 90.9 9.1
Ofloxacin 0.5 0.5 0.5–4 90.9 6.8
Gentamicin 1 1 1 100.0 0.0
Neomycin 0.12 0.25 0.12–2 — —
Bacitracin 32 32 0.25–32 — —
Mupirocin 0.25 0.5 0.12–256 93.2 6.8
Oxacillin-resistant CoNS (174)
Omiganan pentahydrochloride (CA MH broth) 4 4 0.5–16 — —
Omiganan pentahydrochloride (UA MH broth) 2 4 0.25–4 — —
Vancomycin 1 2 0.5–2 100.0 0.0
Penicillin 8 8 0.06–8 1.7 98.3
Ciprofloxacin 2 2 0.25–2 31.6 66.7
Ofloxacin 4 4 0.5–4 32.2 66.7
Gentamicin 2 8 1–8 — —
Neomycin 0.12 16 0.12–16 — —
Bacitracin 32 32 8–32 0.0 100.0
Mupirocin 32 256 0.12–256 48.0 30.1
Oxacillin-susceptible S. aureus (88)
Omiganan pentahydrochloride (CA MH broth) 16 16 2–32 — —
Omiganan pentahydrochloride (UA MH broth) 8 16 1–32 — —
Vancomycin 0.5 1 0.5–1 100.0 0.0
Penicillin 8 8 0.06–8 14.8 85.2
Ciprofloxacin 0.25 0.5 0.25–2 90.9 9.1
Ofloxacin 0.5 0.5 0.5–4 90.9 8.0
Gentamicin 1 1 1–8 — —
Neomycin 0.5 1 0.12–16 — —
Bacitracin 32 32 2–32 2.3 97.7
Mupirocin 0.25 0.25 0.12–256 94.3 5.7
Oxacillin-resistant S. aureus (111)
Omiganan pentahydrochloride (CA MH broth) 16 16 8–64 — —
Omiganan pentahydrochloride (UA MH broth) 8 16 4–64 — —
Vancomycin 1 1 0.5–2 100.0 0.0
Penicillin 8 8 0.5–8 0.0 100.0
Ciprofloxacin 2 2 0.25–2 30.0 70.0
Ofloxacin 4 4 0.5–4 29.7 69.4
Gentamicin 1 8 1–8 65.8 31.5
Neomycin 16 16 0.12–16 — —
Bacitracin 32 32 4–32 — —
Mupirocin 0.25 16 0.12–256 86.5 3.6
Vancomycin-susceptible E. faecalis (87)
Omiganan pentahydrochloride (CA MH broth) 64 128 16–128 — —
Omiganan pentahydrochloride (UA MH broth) 64 128 16–128 — —
Vancomycin 1 2 0.5–2 100.0 0.0
Penicillin 4 8 2–8 100.0 0.0
Ciprofloxacin 1 2 0.25–2 50.6 36.8
Ofloxacin 4 4 1–4 — —
Gentamicin 8 8 2–8 — —
Neomycin 16 16 8–16 — —
Bacitracin 32 32 4–32 — —
Mupirocin 128 256 32–256 0.0 2.3
Vancomycin-nonsusceptible E. faecalis (13)
Omiganan pentahydrochloride (CA MH broth) 64 128 64–128 — —
Omiganan pentahydrochloride (UA MH broth) 64 64 32–64 — —
Vancomycin 32 32 8–32 0.0 92.3
Penicillin 4 4 2–8 100.0 0.0
Ciprofloxacin 2 2 2 0.0 100.0
Ofloxacin 4 4 4 0.0 100.0
Gentamicin 8 8 2–8 — —
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TABLE 1—Continued
Organism (no. tested) and
antimicrobial agenta
MIC (g/ml) % by categoryb
50% 90% Range Susceptible Resistant
Neomycin 16 16 4–16 — —
Bacitracin 32 32 32–32 — —
Mupirocin 64 128 32–128 0.0 0.0
Vancomycin-susceptible E. faecium (44)
Omiganan pentahydrochloride (CA MH broth) 8 16 2–16 — —
Omiganan pentahydrochloride (UA MH broth) 8 8 2–16 — —
Vancomycin 0.5 1 0.25–2 100.0 0.0
Penicillin 8 8 1–8 15.9 84.1
Ciprofloxacin 2 2 0.5–2 14.3 76.2
Ofloxacin 4 4 2–4 — —
Gentamicin 8 8 4–8 — —
Neomycin 16 16 4–16 — —
Bacitracin 32 32 16–32 — —
Mupirocin 0.5 1 0.25–2 100.0 0.0
Vancomycin-nonsusceptible E. faecium (57)
Omiganan pentahydrochloride (CA MH broth) 8 16 2–16 — —
Omiganan pentahydrochloride (UA MH broth) 8 8 2–16 — —
Vancomycin 32 32 32 0.0 100.0
Penicillin 8 8 8 0.0 100.0
Ciprofloxacin 2 2 2 0.0 100.0
Ofloxacin 4 4 4 — —
Gentamicin 8 8 2–8 — —
Neomycin 16 16 4–16 — —
Bacitracin 32 32 8–32 — —
Mupirocin 1 1 0.25–4 100.0 0.0
Beta-hemolytic streptococci (102)
Omiganan pentahydrochloride (CA MH broth) 16 32 2–128 — —
Omiganan pentahydrochloride (UA MH broth) 16 32 1–64 — —
Vancomycin 0.25 0.5 0.06–1 100.0 —
Oxacillin 0.25 0.25 0.25–2 — —
Penicillin 0.06 0.06 0.06–0.5 99.0 —
Ciprofloxacin 0.5 1 0.25–2 — —
Ofloxacin 1 2 0.5–4 99.0 1.0
Gentamicin 8 8 1–8 — —
Neomycin 16 16 4–16 — —
Bacitracin 8 32 0.25–32 — —
Mupirocin 0.12 1 0.12–1 100.0 0.0
Penicillin-susceptible viridans group streptococci (66)
Omiganan pentahydrochloride (CA MH broth) 64 256 4–512 — —
Omiganan pentahydrochloride (UA MH broth) 64 256 1–512 — —
Vancomycin 0.5 0.5 0.12–1 100.0 —
Oxacillin 0.25 0.25 0.25–0.5 — —
Penicillin 0.06 0.12 0.06–0.12 100.0 0.0
Ciprofloxacin 1 2 0.25–2 — —
Ofloxacin 2 4 0.5–4 — —
Gentamicin 4 8 1–8 — —
Neomycin 16 16 0.12–16 — —
Bacitracin 16 32 0.25–32 — —
Mupirocin 1 1 0.12–256 98.5 1.5
Penicillin-nonsusceptible viridans group streptococci (34)
Omiganan pentahydrochloride (CA MH broth) 64 256 4–256 — —
Omiganan pentahydrochloride (UA MH broth) 64 256 2–256 — —
Vancomycin 0.5 0.5 0.12–0.5 100.0 —
Oxacillin 1 2 0.25–2 — —
Penicillin 0.5 4 0.25–8 0.0 14.7
Ciprofloxacin 2 2 0.5–2 — —
Ofloxacin 2 4 1–4 — —
Gentamicin 2 8 1–8 — —
Neomycin 16 16 2–16 — —
Bacitracin 8 32 0.5–32 — —
Mupirocin 1 32 0.25–256 85.3 2.9
Bacillus spp. (103)
Omiganan pentahydrochloride (CA MH broth) 16 32 0.25–64 — —
Omiganan pentahydrochloride (UA MH broth) 16 32 0.25–64 — —
Continued on following page
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TABLE 1—Continued
Organism (no. tested) and
antimicrobial agenta
MIC (g/ml) % by categoryb
50% 90% Range Susceptible Resistant
Vancomycin 1 2 0.06–32 98.1 1.0
Oxacillin 2 2 0.25–2 31.1 68.9
Penicillin 8 8 0.06–8 26.2 73.8
Ciprofloxacin 0.25 0.5 0.25–2 95.1 4.9
Ofloxacin 0.5 1 0.5–4 94.2 3.9
Gentamicin 1 1 1–4 100.0 0.0
Neomycin 0.5 1 0.12–16 — —
Bacitracin 32 32 0.25–32 — —
Mupirocin 256 256 0.12–256 14.6 76.7
Corynebacterium spp. (103)
Omiganan pentahydrochloride (CA MH broth) 4 8 0.25–64 — —
Omiganan pentahydrochloride (UA MH broth) 2 4 0.25–32 — —
Vancomycin 0.5 0.5 0.12–32 99.0 1.0
Oxacillin 2 2 0.25–2 22.3 77.7
Penicillin 4 8 0.06–8 17.5 82.5
Ciprofloxacin 2 2 0.25–2 35.9 62.1
Ofloxacin 4 4 0.5–4 36.9 61.2
Gentamicin 1 8 1–8 75.7 19.4
Neomycin 0.5 16 0.12–16 — —
Bacitracin 8 32 0.25–32 — —
Mupirocin 256 256 0.12–256 1.9 97.1
Enterobacter spp. (100)
Omiganan pentahydrochloride (CA MH broth) 32 256 8–512 — —
Omiganan pentahydrochloride (UA MH broth) 16 128 4–512 — —
Ciprofloxacin 0.25 0.5 0.25–2 94.0 4.0
Ofloxacin 0.5 1 0.5–4 94.0 3.0
Gentamicin 1 1 1–8 94.9 5.1
Neomycin 1 2 0.25–16 — —
Bacitracin 32 32 32 — —
Polymyxin B 0.25 16 0.25–32 — —
E. coli (108)
Omiganan pentahydrochloride (CA MH broth) 16 32 8–64 — —
Omiganan pentahydrochloride (UA MH broth) 8 16 4–32 — —
Ciprofloxacin 0.25 2 0.25–2 84.3 15.7
Ofloxacin 0.5 4 0.5–4 83.3 15.7
Gentamicin 1 1 1–8 91.7 8.3
Neomycin 1 2 0.5–16 — —
Bacitracin 32 32 32–32 — —
Polymyxin B 0.25 0.25 0.25–0.5 — —
Klebsiella spp. (101)
Omiganan pentahydrochloride (CA MH broth) 32 128 8–512 — —
Omiganan pentahydrochloride (UA MH broth) 16 128 4–512 — —
Ciprofloxacin 0.25 0.5 0.25–2 92.0 6.0
Ofloxacin 0.5 2 0.5–4 92.1 5.9
Gentamicin 1 1 1–8 95.0 3.0
Neomycin 1 2 0.12–16 — —
Bacitracin 32 32 32 — —
Polymyxin B 0.25 0.25 0.25–16 — —
P. aeruginosa (102)
Omiganan pentahydrochloride (CA MH broth) 128 256 16–256 — —
Omiganan pentahydrochloride (UA MH broth) 32 64 16–256 — —
Ciprofloxacin 0.25 2 0.25–2 78.4 19.6
Ofloxacin 1 4 0.5–4 69.6 22.5
Gentamicin 2 8 1–8 86.3 10.8
Neomycin 4 16 1–16 71.6 —
Bacitracin 32 32 32 — —
Polymyxin B 0.5 0.5 0.25–32 — —
C. albicans (104)
Omiganan pentahydrochloride 64 64 32–512 — —
Nystatin 2 2 1–32 — —
Continued on following page
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ATCC 22019 and Candida krusei ATCC 6258 (Anderegg et al.,
letter).
All frozen panels representing the three medium types were
included in a 120-day stability study. Panels were tested in
triplicate at days 0, 7, 14, 21, 28, 45, 60, 90, and 120 postmanu-
facture for each of five bacterial and two yeast QC strains.
Ten strains were tested by kill curve methodology to evalu-
ate the bactericidal activity of omiganan pentahydrochloride
(8, 9). Bacterial kill curve studies were performed with CA MH
broth, and Candida albicans kill curve studies were performed
with RPMI 1640 broth and MOPS buffer. Omiganan pentahy-
drochloride activity was tested at one, two, four, and eight
times the MIC at timed intervals of 0, 0.5, 2, 6, and 24 h.
Minimal bactericidal and fungicidal concentrations (MBCs
and MFCs, respectively) were assessed by plating the broth
from the MIC well and from the three log2 dilutions above the
MIC for each organism onto appropriate growth media. Col-
onies of the starting inoculum were counted at the times the
MICs were determined. The lowest concentration of antimi-
crobial agent that kills 99.9% of the starting test inoculum is
defined as the MBC endpoint (4). A total of eight strains,
including S. pneumoniae ATCC 49619, S. aureus ATCC 29213,
E. faecalis ATCC 29212, P. aeruginosa ATCC 27853, E. coli
ATCC 25922, S. aureus 24-1920A, C. albicans 15-10082A, and
C. albicans 13-13547A, were selected for this experiment.
Omiganan pentahydrochloride was very active against all
gram-positive species tested (Table 1). The rank order of the
gram-positive pathogens according to their susceptibilities to
omiganan pentahydrochloride (the MICs at which 50% of the
isolates were inhibited [MIC50s]) was as follows: oxacillin-sus-
ceptible coagulase-negative staphylococcus (CoNS)  oxacil-
lin-resistant CoNS Corynebacterium spp. (MIC50, 4 g/ml)
vancomycin-susceptible Enterococcus faecium  vancomycin-
resistant E. faecium (MIC50, 8 g/ml) oxacillin-susceptible S.
aureus  oxacillin-resistant S. aureus  beta-hemolytic strep-
tococci  Bacillus spp. (MIC50, 16 g/ml)  vancomycin-sus-
ceptible E. faecalis  vancomycin-nonsusceptible E. faecalis 
penicillin-susceptible viridans group streptococci  penicillin-
nonsusceptible viridans group streptococci (MIC50, 64 g/ml).
Omiganan pentahydrochloride was equally active against ox-
acillin-susceptible and -resistant CoNS (MIC90, 8 and 4 g/ml,
respectively). Omiganan pentahydrochloride MICs for S. au-
reus (MIC90s, 16 g/ml) were generally twofold higher than
those for CoNS.
Omiganan pentahydrochloride was eightfold more active
against E. faecium (MIC50, 8 g/ml) than against E. faecalis
(MIC50, 64 g/ml), and its activity was not affected by vanco-
mycin resistance. Against beta-hemolytic streptococci, omiga-
nan pentahydrochloride MICs ranged from 2 to 128 g/ml,
with a MIC90 of 32 g/ml. Among the gram-positive species
tested, the highest omiganan pentahydrochloride MICs for
both penicillin-susceptible and -nonsusceptible isolates were
those for viridans group streptococci (MIC90, 256 g/ml). Omi-
ganan pentahydrochloride showed excellent in vitro activity
against Bacillus spp. (MIC50, 16 g/ml), and omiganan penta-
hydrochloride MICs were lowest for Corynebacterium spp.,
with a MIC50 of only 4 g/ml.
In general, MICs with UA MH broth were equal or twofold
lower than those with CA MH broth for the bacterial species
evaluated in the present study (Table 1). The highest variation
was seen with P. aeruginosa, for which the MIC50 dropped from
128 g/ml in CA MH broth to 32 g/ml in UA MH broth. This
TABLE 1—Continued
Organism (no. tested) and
antimicrobial agenta
MIC (g/ml) % by categoryb
50% 90% Range Susceptible Resistant
Fluconazole 0.25 1 0.25–512 96.2 3.8
Amphotericin B 0.5 0.5 0.12–1 100.0 —
C. glabrata (27)
Omiganan pentahydrochloride 256 512 128–512 — —
Nystatin 2 2 1–4 — —
Fluconazole 16 32 4–256 44.4 7.4
Amphotericin B 0.5 1 0.25–1 100.0 —
C. krusei (26)
Omiganan pentahydrochloride 32 64 16–256 — —
Nystatin 2 2 2–32 — —
Fluconazole 16 32 0.5–64 11.5 3.8
Amphotericin B 1 1 0.5–1 100.0 —
C. parapsilosis (30)
Omiganan pentahydrochloride 128 256 32–256 — —
Nystatin 2 2 2 — —
Fluconazole 1 2 0.25–32 96.7 0.0
Amphotericin B 0.5 0.5 0.5–1 — —
C. tropicalis (27)
Omiganan pentahydrochloride 16 32 8–64 — —
Nystatin 2 2 1–2 — —
Fluconazole 0.5 1 0.25–64 96.3 3.7
Amphotericin B 1 1 0.5–1 100.0 —
a With mupirocin, isolates were considered susceptible when MICs were 8 g/ml and resistant (high level) when MICs were 256 g/ml.
b —, no breakpoint has been established by the NCCLS (10, 12).
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TABLE 2. Kill curve kinetic studies in cation-deficient MH broth for 10 selected organisms with four concentrations of omiganan
pentahydrochloride and monitoring at 0.5, 2, 6, and 24 h
Organism Concn testedd
CFU/ml at time indicated (h) MIC
(g/ml)0 0.5 2 6 24
S. aureus ATCC 29213 Control 4.8E6 5.7E6 3.3E7 5.2E8 8.5E8 8
MIC 2.0E6 1.3E5 1.6E4 3.2E8
2  MIC 1.2E6 3.8E4 1.6E3a 6.2E5
4  MIC 3.8E5 7.8E3 1.3E2a 1.1E4
8  MIC 1.5E5 1.1E3a 1.0E2a 1a
S. aureus MBI 105b Control 2.8E6 4.8E6 2.0E7 3.7E8 7.1E8 8
MIC 1.3E5 1.5E4 5.9E4 2.3E7
2  MIC 1.8E4 1.7E3a 7.7E6 6.1E6
4  MIC 1.2E4 2.3E2a 1.7E5 4.9E5
8  MIC 7.5E3 2.9E2a 1a 6.0E2a
Staphylococcus epidermidis 6–313Ab Control 1.8E5 1.3E5 1.7E5 4.7E6 1.3E8 2
MIC 3.6E4 2.0E3 2.0E4 5.8E4
2  MIC 1.7E4 8.5E2 1a 1.0E5
4  MIC 4.7E3 1.6E2a 1a 8.0E4
8  MIC 1.2E3 1a 1a 1.0E3
E. faecium 27–308A (VSE) Control 2.1E6 2.1E6 2.2E7 3.2E8 6.0E8 8
MIC 9.5E5 2.0E5 1.7E4 3.3E5
2  MIC 3.6E5 3.2E4 1.4E3a 3.1E2a
4  MIC 4.4E4 2.7E3 1.3E2a 6a
8  MIC 7.4E3 2.6E3 5a 1a
E. faecium 15–206Ac Control 7.3E5 2.0E6 9.1E6 3.1E8 3.5E8 8
MIC 3.5E5 3.4E5 1.4E5 9.8E5
2  MIC 2.0E5 4.2E4 8.5E3 7.6E3
4  MIC 1.2E5 2.5E3 3.2E2a 4.a
8  MIC 1.4E4 6a 1a 1a
E. coli ATCC 25922 Control 1.4E6 2.8E6 4.0E7 5.0E8 8.7E8 16
MIC 1.7E6 1.4E6 1.7E6 1.9E8
2  MIC 1.5E6 6.0E5 3.8E4 2.9E8
4  MIC 2.2E5 5.4E4 3.4E4 5.7E2a
8  MIC 9.0E2a 2.3E2a 1a 1a
Klebsiella pneumoniae 21-1940A Control 9.0E5 4.3E6 1.1E8 4.4E8 6.7E8 16
MIC 3.5E6 1.3E7 2.3E8 7.5E8
2  MIC 2.1E6 4.9E5 8.2E4 3.0E8
4  MIC 2.7E5 2.3E4 1.1E4 7.3E3
8  MIC 2.7E4 6.5a 1a 1a
Acinetobacter baumannii 101-2823A Control 3.2E6 4.4E6 2.7E7 7.5E7 2.2E9 8
MIC 6.7E6 1.4E7 2.0E7 1.3E9
2  MIC 4.2E6 1.6E5 7.2E4 8.2E5
4  MIC 1.2E6 6.6E2a 1a 1a
8  MIC 4.1E2a 1a 1a 1a
P. aeruginosa ATCC 27853 Control 2.8E6 2.3E6 2.6E7 2.2E8 3.0E9 16
MIC 3.4E6 3.2E6 1.6E8 7.5E8
2  MIC 3.4E6 1.9E7 9.1E7 1.8E9
4  MIC 2.5E3a 2.2E3a 1.0E5 2.1E8
8  MIC 1.0E2a 4.3E2a 4.3E4 1.2E6
C. albicans 15-10082A Control 3.0E6 2.5E6 3.5E6 8.9E6 2.3E7 64
MIC 2.0E6 1.9E6 3.8E6 9.3E6
2  MIC 1.9E6 2.4E5 5.6E3 3.0E4
4  MIC 3.5E5 9.1E2a 1a 1a
8  MIC 9.3E3 2a 1a 1a
a Indicates bactericidal results (3 log10 killing), usually occurring at 2 to 6 h.
b Oxacillin-resistant strains.
c Vancomycin-resistant strains.
d 2  MIC, 4  MIC, and 8  MIC, two, four, and eight times the MIC, respectively.
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trend was also observed in QC studies with P. aeruginosa
strains.
The in vitro activity of omiganan pentahydrochloride against
the gram-negative isolates is also summarized in Table 1. The
rank order of susceptibilities by the MIC50s of omiganan pen-
tahydrochloride for the gram-negative organisms was as fol-
lows: E. coli (MIC50, 16 g/ml)  Enterobacter spp.  Kleb-
siella spp. (MIC50, 32 g/ml)  P. aeruginosa (MIC50, 128
g/ml). Omiganan pentahydrochloride MICs were highest for
Enterobacter spp. among the bacterial pathogens tested in the
present study, with a MIC90 of 256 g/ml.
Omiganan pentahydrochloride demonstrated excellent in
vitro activity against the Candida species. The rank order of in
vitro activity levels according to the MIC50s of omiganan pen-
tahydrochloride for the Candida species was as follows: C.
tropicalis (MIC50, 16 g/ml)  C. krusei (MIC50, 32 g/ml) 
C. albicans (MIC50, 64 g/ml)  C. parapsilosis (MIC50, 128
g/ml)  C. glabrata (MIC50, 256 g/ml). All Candida spp.
isolates evaluated showed a narrow range of omiganan penta-
hydrochloride MICs. MICs of 64 g/ml were observed for 84%
of the C. albicans spp., while the MICs for 97% of all strains
were between 32 and 128 g/ml.
When the MBC and MFC tests were performed with CA
MH broth, the MBCs were the same or two- to fourfold
greater than the MICs (data not shown). For tests performed
with UA MH broth, the MICs were two- to fourfold lower than
those observed for tests carried out with the CA MH broth,
and the corresponding MBCs were either equal to the MICs or
twofold higher (data not shown). For C. albicans, the MFCs
were either equal to or twofold higher than the MICs. The
highest recorded MBC or MFC for any bacterial or yeast
isolate tested was 128 g/ml.
Table 2 summarizes the time-kill curve experiments for the
10 organisms tested. A clear pattern of rapid bactericidal ac-
tivity was noted within 2 to 6 h. Increased concentrations of
omiganan pentahydrochloride enhanced the bactericidal ef-
fect. Excellent concentration-dependent killing by omiganan
pentahydrochloride was demonstrated against strains of van-
comycin-resistant enterococci and oxacillin-resistant staphylo-
cocci. However, several strains, including both oxacillin-resis-
tant staphylococcal strains, demonstrated regrowth to baseline
levels at 24 h. Omiganan pentahydrochloride was also rapidly
fungicidal against the C. albicans strain.
Frozen panels including omiganan pentahydrochloride and
comparator antimicrobial agents appeared to remain stable
over the 120-day monitored period (data not shown). All re-
sults from triplicate testing recorded for seven ATCC control
strains between days 7 and 120 were within the recently pro-
posed QC range (Anderegg et al., letter).
In summary, omiganan pentahydrochloride was highly active
against the bacterial and yeast isolates tested in this study.
Omiganan pentahydrochloride results were slightly higher (1
to 2 log2 dilution steps) when bacteria were tested in CA MH
broth than in CU MH broth. The cation concentration effect
on omiganan pentahydrochloride MICs varied among the
pathogens tested. Omiganan pentahydrochloride demonstrat-
ed rapid, concentration-dependent bactericidal and fungicidal
activity with MBCs (or MFCs) equal to the MICs or only up to
fourfold greater. The results of this study demonstrate that
omiganan pentahydrochloride was active against contempo-
rary bacteria and Candida spp. and indicate that this com-
pound should be further evaluated for possible clinical use,
especially for prevention of catheter-related infections and
therapy for cutaneous infections (6, 7).
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